Global Neurology Academy

NEDAs Role in the Treatment of MS

NEDAs Role in the Treatment of MS
    Join us as Lawrence Sherman speaks with Dr. Andrew Chan on the utility of NEDA-3 and NEDA-4 in MS treatment, as well as other considerations to imp...
    • Overview

      Join us as Lawrence Sherman speaks with Dr. Andrew Chan on the utility of NEDA-3 and NEDA-4 in MS treatment, as well as other considerations to improve MS treatment monitoring and the potential role of cladribine in the management of MS.

      This interview was conducted while at the Multiple sclerosis: meeting unmet needs through scientific discoveries and clinical practice conference. This international conference was conducted by one of our partners, EXCEMED. 


      As of August 2018, Cladribine was approved in Europe for the treatment of highly active relapsing multiple sclerosis (RMS). All studies presented in this education are still accurate. To learn more about this approval, click here.

    • Learning Objectives

      At the completion of this module, participants should be better able to:

      1. Understand the utility of NEDA-3 in the management of MS
      2. Appreciate the differences between NEDA-3 and NEDA-4 and the key distinction between them
      3. Evaluate the relative value of cladribine as a potential agent in the management of MS
    • Accreditation and Credit Designation Statements

      The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be available for immediate download.

    • Target Audience

      This course is designed to meet the Continuing Medical Education needs of the practicing neurologist.

    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

      Original Release Date: 14 May 2016
      Expiration Date: 14 May 2017

    • Disclosure of Conflicts of Interest

      In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


      Andrew Chan, MD
      Neurocenter Inselspital
      University Hospital Bern
      Bern, Switzerland
      Financial Relationship Disclosure:
      Receipt of Intellectual Property Rights/Patent Holder: Antibodyprofile and Protagen
      Consulting Fees: Bayer, Biogen, Genzyme, Roche and Novartis
      Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Roche and Teva
      Contracted Research: Biogen, Genyzme and Novartis


      Lawrence Sherman, FACEHP, CHCP
      Senior Vice President, Educational Strategy TOPEC Global
      Financial Relationship Disclosure:
      No relationships reported


      •Sean T. Barrett, CHCP has nothing to disclose.
      •Barry A. Fiedel, PhD has nothing to disclose.
      •Kia K. Gray, MPH has nothing to disclose.
      •Ashley Pluta has nothing to disclose.
      •Lawrence Sherman, FACEHP, CHCPhas nothing to disclose.

    • Instructions

      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Omnia-Prova Education Collaborative (TOPEC) does not recommend the use of any agent outside of the labeled indications.

      The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      Contact Information
      In case of technical needs, please contact:

    • Disclaimer

      All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

      The material presented in this Global Multiple Sclerosis Academy continuing medical education activity does not necessarily reflect the views and opinions of Global Multiple Sclerosis Academy . NeitherGlobal Multiple Sclerosis Academy nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    Facebook Comments

    Sign up for the Global Neurology Academy newsletters.
    Comprehensive Neurology Education.

    Better education for a better you.

    * Required

    We’re glad to see you’re enjoying Global Neurology Academy…
    but how about a more personalized experience?

    Register for free